Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 166

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 166
---
72 |

We are developing
biological and pharmaceutical products. Patent applications for these products and product candidates may not have been filed yet, and
we may not be able to obtain patents on such products. The patent prosecution process for biological and pharmaceutical products is expensive
and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or
in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before
it is too late to obtain patent protection. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain
and involve complex legal and factual questions for which important legal principles remain unresolved in the United States. The patent
situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in
the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth
of claims that may be allowed or enforced in our patents or in third-party patents.

Because patent
applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that
we or our licensors were the first to file any patent application related to our products. Furthermore, for United States applications
in which all claims are entitled to a priority date before March 16, 2013 (the date when United States patent law changed from granting
rights to the first-to-invent to the first-to-file), an interference proceeding can be provoked by a third-party or instituted by the
United States Patent and Trademark Office (the “USPTO”), to determine who was the first to invent any of the subject matter
covered by the patent claims of applications filed by us or our licensors. We cannot be certain that we or our licensors are the first
to invent the inventions covered by pending patent applications entitled to a priority date before March 16, 2013, and, if we or our licensors
are not, those applications may be subject to priority disputes.

We or our licensors
may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be
prior art of which we are not aware that may affect the validity or enforceability of a pending patent claim, which may be subject to
a third-party preissuance submission of prior art to the USPTO. There also may be prior art of which we or